Kiadis Pharma is a clinical stage biopharmaceutical company
developing innovative and potentially life‑saving therapies for
patients with late stage blood cancers and related disorders in
need of a transplant, an area of significant unmet medical need.
ATIR™ is Kiadis Pharma’s lead product in development and enables partially
matched stem cells from family members (haploidentical donors) to be used
in reconstituting the immune system of blood cancer patients after a bone
marrow transplantation without eliciting severe or life threatening Graft-versus-Host-Disease (GvHD).
The Company is currently sponsoring a multi‑center Phase II
clinical trial for ATIR™ and is collaborating with renowned centers in Europe and North America.
December 9, 2014Kiadis Pharma presents positive data from a pre-specified interim analysis of the Phase II clinical program with its lead product ATIR™
October 30, 2014Kiadis Pharma’s lead product ATIR™ granted Orphan Drug Designation by EMA for the treatment of Acute Myeloid Leukemia
September 3, 2014Kiadis Pharma appoints Jeroen Rovers as its Chief Medical Officer
March 24, 2014Kiadis Pharma organizes a satellite symposium on March 30, 2014 at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation
Click to download the Company Fact Sheet which provides a valuable insight into where Kiadis Pharma stands today. It summarizes what the Company's lead product ATIR™ is about, its market potential and the progress that is being made in clinical development.
Denis-Claude Roy, MD, Professor of Medicine at the University of Montreal, presented interim results of Kiadis Pharma’s ongoing international multi-center Phase II study at the 2014 annual meeting of ASH (American Society of Hematology). The study investigates the safety and efficacy of adding ATIR™ to a T-cell depleted haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). A copy of the abstract can be found here.
ATIR™ has recently been awarded a third Orphan Drug Designation, for the treatment of AML in the European Union.
Advanced Therapies Investor Day
Watch the company presentation by Manfred Rüdiger at the Advanced Therapies Investor Day held on November 13, 2014 in London, UK
JP Morgan Annual Healthcare Conference
January 12-16, 2015 - San Francisco, USA
Phacilitate Cell & Gene Therapy Forum
January 26-28, 2015 - Washington DC, USA
European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting
March 22-25, 2015 - Istanbul, Turkey